W. Middlekauff

Part of Tourmaline Bio, Inc., Tourmaline Sub, Inc. is a late-stage clinical biotechnology company based in New York, NY. The company's lead program, Tour006, is an anti-IL-6 antibody with high binding affinity and a naturally long half-life. Tour006 has been studied in over 400 autoimmune patients across six clinical trials. Tourmaline Sub plans to develop Tour006 for thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD), with additional indications being considered. The company, founded in 2021 by Sandeep Kulkarni and Caley M. Castelein, is focused on developing transformative medicines for patients with life-altering immune diseases. Sandeep Kulkarni has been the CEO since 2021. Tourmaline Sub was acquired by Talaris Therapeutics, Inc. on October 19, 2023, for $43.50 million.

Castle Creek Biosciences, Inc. engages in the research and development of gene therapies for patients with rare and genetic diseases. It offers treatment for Recessive Dystrophic Epidermolysis Bullosa (RDEB) and localized Scleroderma; and topical ointment for Epidermolysis Bullosa Simplex. The company was founded by Jeffrey S. Aronin in September 2018 and is headquartered in Exton, PA.

Kolltan Pharmaceuticals, Inc. engaged in the development of monoclonal antibody drugs. It focused on the discovery and development of novel antibody-based drugs targeting receptor tyrosine kinases (RTKs) for the treatment of cancer and other diseases. The company was founded by Arthur G. Altschul, Jr. and Joseph P. Schlessinger on November 16, 2007 and was headquartered in New Haven, CT.

Medarex, Inc. provides commercial physical and biological research services. The company's UltiMAb, a human antibody development system creates and develops antibodies products for cancer, rheumatoid arthritis, inflammatory, autoimmune, and infectious diseases. The company was founded in 1987 and is headquartered in Princeton, New Jersey.

Part of Endo International Plc, Algos Pharmaceutical Corp. develops and makes pain management products including narcotic drugs. The company is based in Neptune, NJ. Algos Pharmaceutical was acquired by Endo Health Solutions, Inc. on July 17, 2000 for $243.89 million.

Cooley Goodword LLP is the law firm specializes in providing services to both new and established information technology and life sciences companies. Cooley also provides counsel in areas of business law that include trade regulation, employment and labor, investment banking issues, securities litigation, IPOs, mergers and acquisitions, patent enforcement and venture capital funding. It is located in Palo Alto, CA.

SpliceBio SL is a genetic medicines company based in Barcelona, Spain. The Spanish company harnesses its proprietary protein splicing platform to develop the next generation of gene therapies. SpliceBio's platform offers the potential to address diseases that currently cannot be treated with gene therapies because the necessary gene is too large to be delivered by -associated virus (AAV) vectors. The company's lead program targets Stargardt disease, a genetic eye disease that causes vision loss in children and adults. SpliceBio's platform is based on technology developed in the Muir lab at Princeton University after more than 20 years of pioneering intein and protein engineering research. The company was founded by Dominguez Silvia Frutos, Miquel Vila-Perelló, and Miquel Vila-Perelló has been the CEO since incorporation.